

Extended Solution Gate OFET-Based Biosensor for Label-Free Glial Fibrillary Acidic Protein Detection with Polyethylene Glycol-Containing Bioreceptor Layer

Jian Song, Jennifer Dailey, Hui Li, Hyun-June Jang, Pengfei Zhang, Jeff Tza-Huei Wang, Allen D. Everett, and Howard E. Katz*

A novel organic field effect transistor (OFET)-based biosensor is described for label-free glial fibrillary acidic protein detection. This study reports the first use of an extended solution gate structure where the sensing area and the organic semiconductor are separated, and a reference electrode is not needed. Different molecular weight polyethylene glycols (PEGs) are mixed into the bioreceptor layer to help extend the Debye screening length. The drain current change is significantly increased with the help of higher molecular weight PEGs, as they are known to reduce the dielectric constant. This study also investigates the sensing performance under different gate voltage (V_g). The sensitivity increases after the V_g is decreased from -5 to -2 V because the lower V_g is much closer to the OFET threshold voltage and the influence of attached negatively charged proteins becomes more apparent. Finally, the selectivity experiments toward different interferents are performed. The stability and selectivity are promising for clinical applications.

signal changes. The analytes can be identified by either chemically binding specific receptors or modifying specific detection layers on the sensing area. Challenges in using this technology can include insufficient sensitivity, poor stability, and complicated fabrication processes.

Various possible mechanisms have been proposed for achieving better performance in OFET-based biosensors. Most of the studies are based on the “bottom gate” and “solution gate” structure devices, which put the solution sensing area upon the organic semiconductor and can exhibit relatively high sensitivities.^[3,5,6,18,20,22] In order to protect the organic semiconductor from being influenced by water, several types of water-resistant layers have been attached or placed thereon. Unfortunately, these

1. Introduction

Organic field effect transistors (OFETs) are an emerging alternative for sensing technology.^[1–14] In the past two decades, these devices have garnered increasing interest for potential applications such as gas concentration and mechanical force sensing.^[1,9,15] Also, because of inherent advantages including low cost, simple operation, large functional area, and biocompatibility, FET-based biosensors have been applied to detect many biological analytes.^[8,16–24] Since most of the biomolecules influence electronic properties of liquids and/or their interfaces, label-free detection becomes possible by reading electrical

detectors can still have stability problems during prolonged detection times because most organic semiconductors are considerably sensitive to high humidity. In another approach, researchers have presented the “extended gate” structure device, which can separate the sensing area from the transistor itself.^[7,25–28] In one promising example, Minami and co-workers developed a highly selective nitrate detector using one version of an extended gate geometry. This type of device shows improved stability, but almost all the devices with this architecture, including those from the Tokito and co-workers, need to add reference electrodes in the solution sensing area, bringing an additional degree of complication. Bonfiglio and co-workers proposed a concept of a remote floating gate influencing the current of the OFET, with the analyte solution capacitively coupled to the floating gate.^[23,24] The detector functions as a label-free DNA sensor without a reference electrode, simultaneously having the advantages of simple structure and good stability. In the architecture of Bonfiglio and co-workers, a control capacitor separates the gate electrode from the surface of the substrate, and the floating gate connects this signal electrically to the base of the sensing area. In our work, we describe a novel extended “solution gate” structure device that differs from these aforementioned examples in a few key ways. First, no reference electrode is required for our device functionality, simplifying the overall system. Second, the gate electrode is placed directly into the sensing solution electrolyte, altering the overall sensitivity of the device. The sensor can

Dr. J. Song, J. Dailey, Dr. H. Li, H.-J. Jang, P. Zhang,
Prof. J. T.-H. Wang, Prof. A. D. Everett, Prof. H. E. Katz
Department of Materials Science and Engineering
Johns Hopkins University
3400 North Charles Street, Baltimore, MD 21218, USA
E-mail: hekatz@jhu.edu



P. Zhang, J. T.-H. Wang
Department of Biomedical Engineering
Johns Hopkins University
3400 North Charles Street, Baltimore, MD 21218, USA
A. D. Everett
Johns Hopkins Medical Institutes
Children's Center
1800 Orleans Street, Baltimore, MD 21287, USA

DOI: 10.1002/adfm.201606506

detect low-concentration, label-free protein analytes in solution in a stable manner.


The Debye screening length, beyond which voltage changes are not sensed in a solution, is a great challenge for FET-based biosensors.^[21,29,30] To increase the length beyond bioanalyte/bioreceptor complex dimensions, sensors are often used in relatively low ionic strength solutions (i.e., 0.01X PBS, where PBS refers to the standard pH 7.4 “phosphate buffer solution” and X indicates dilution with water), which do not realistically represent biological fluids. It was reported that the polymer poly(ethylene glycol) (PEG) can substantially change the dielectric properties in aqueous solutions and thus serve to increase the sensing response seen at the calculated Debye length, thus increasing the “effective Debye screening length” for a given solution ionic strength, and the higher molecular weight PEG can decrease the dielectric constant more effectively than lower ones.^[31] Lieber and co-workers used PEG on the inorganic field-effect-transistor-based sensor for biodetection in high ionic strength solution (100×10^{-3} M PBS).^[30] Inspired by these previous studies, we further investigated the influences of different molecular weight PEG-containing bioreceptor layers to help overcome the Debye screening length.

Since one present clinical urgency is to investigate brain injuries as quickly as possible, we chose glial fibrillary acidic protein (GFAP) as a model analyte.^[32–37] GFAP is a major protein associated with glial cells in the central nervous system, being released into human blood when brain injuries occur. The presence of 1.5 ng mL^{-1} GFAP in blood indicates that a patient has moderate brain damage.^[37] The isoelectric points (pI points) for anti-GFAP antibody and GFAP are 5.7 and 5.4, respectively. According to our previous research, both GFAP and the corresponding antibody are negatively charged in pH = 7.4 buffer solution.^[38] Finally, we measured the sensitivity under different gate potential (V_g) for a further optimization. Dixon's *Q*-tests on each group of data with removed outliers^[39] were used to determine significant differences among bioreceptor material compositions.

2. Results and Discussion

2.1. Device Architecture and Chemical Characterization

Pentacene (Scheme 1a) was selected as the semiconductor material due to its high mobility and good stability. The OFET sensor consists of two major sections (shown in Scheme 1b): the drive unit (OFET) and the detection area (extended solution gate). For the drive unit, interdigitated Au electrodes were deposited on pentacene films to define a large active area ($7 \text{ mm} \times 7 \text{ mm}$). It was found that interdigitated electrodes can yield increased absolute current changes due to increased surface area.^[40] Therefore, the sensors can work under a low enough gate voltage (-2 V) to maintain biological compatibility for proteins in aqueous solution. According to the typical transfer and output curves operated in air (shown in Figure 1), the devices show excellent linear and saturation regime characteristics with a hole mobility of $0.69 \pm 0.07 \text{ cm}^2 \text{ V}^{-1} \text{ s}^{-1}$, an on/off ratio of 26.0 ± 5.7 at V_g of -2 V , and a threshold voltage of $0.12 \pm 0.1 \text{ V}$. The OFETs were working under $V_{ds} = -2 \text{ V}$ and $V_g = 0$ to -2 V .



Scheme 1. a) Chemical structures of pentacene, PS-MA, and PEG. b) Device architecture of extended solution gate.

On the extended solution gate, anti-GFAP was immobilized on the (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) (EDC)/N-hydroxysuccinimide sodium (NHS) treated polystyrene-co-methacrylic acid (PS-MA) layer. The chemical structure of PS-MA is shown in Scheme 1a. EDC is soluble in water and most organic solvents, and is widely used in carboxylic group activation for dehydration–condensation reaction.^[38] Since the EDC-derivatized compound is unstable, NHS is frequently used with EDC to increase coupling efficiency. The NHS-activated carboxyl groups of the polymer then react with a given antibody to immobilize it on the PS-MA layer. The chemical structure and reaction equation are shown in Figure S2 (Supporting Information). We use $^1\text{H-NMR}$ to quantify the extent of carboxyl group as Figure S3 (Supporting Information). The $^1\text{H-NMR}$ result shows that the styrene:methacrylic acid molar ratio is about 3:1. Before EDC/NHS treatment, the carboxylic acid $^1\text{H-NMR}$ peak appears at 11.88 ppm. After EDC/NHS treatment, this peak completely disappears, indicating that 100% yield of carboxyl group activation was achieved. In addition, new proton peaks for NHS at 2.28 ppm and for EDC at 4–4.2 ppm were observed, indicating that the carboxylic acid groups were completely activated by EDC and NHS, desirable for high antibody surface coverage. Also, the morphologies of the PS-MA film, EDC/NHS treated PS-MA film, and washed EDC/NHS treated PS-MA film were examined by optical microscopy, as shown in Figure S4 (Supporting Information). It can be observed that the PS-MA film provides a




Figure 1. Typical a) transfer curve and b) output curve of a pentacene OFET tested in air.

smooth surface. After treatment by EDC and NHS, the surface (Figure S4b, Supporting Information) became rough because the concentrations of EDC and NHS are 3 times and 1.5 times higher than PS-MA in solution, respectively. The excess chemicals likely caused some aggregation of polymer and reactant, as visible from some small particulates forming in solution even after filtration through a 0.4 μm filter. These particulates were not observed when EDC and NHS were not added to solution. After washing the surface with deionized (DI) water, the film surface (Figure S4c, Supporting Information) regained some smoothness, as the DI water removed these unbound particles. Roughness measurements were taken of both substrates with and without 8000 MW PEG using an optical microscope and associated software (shown in Figure S4d,e, Supporting Information). The images show no indication of obvious phase separation. Even though the roughness increased from 1.3 to 3.1 μm with the addition of PEG, the PEG-containing sample, if anything, showed more uniform morphology than the non-PEG sample and the feature shapes are similar in both samples. This indicates that there are not likely to be phase-separated regions of predominantly polymer and predominantly PEG on the size scale of micrometers or larger. Also, the UV-vis transmission spectra of the two samples, corrected for thickness, are nearly identical (Figure S4f, Supporting Information), indicating similar light-scattering features in both samples. Transfer curves for different molecular weight PEGs in liquid are shown in Figure S4g (Supporting Information).

Furthermore, we placed fluorescein isothiocyanate (FITC)-labeled anti-GFAP on the bioreceptor layer to confirm the binding property between PS-MA and antibody. The images are shown in **Figure 2**. First, we put 100 $\mu\text{g mL}^{-1}$ FITC labeled anti-GFAP directly on the bare substrate and PS-MA layer before activation by EDC/NHS (shown in Figure 2a,b). After 6 h, the surfaces were washed by PBS 5 times to remove any unbound anti-GFAP. We can see that hardly any antibody was immobilized on the substrate, indicating low nonspecific binding. Figure 2c shows the result of the device modified by the EDC/NHS activated PS-MA layer.

After FITC-labeled anti-GFAP was applied to the device with the same procedure, visible fluorescence was observed. Compared to Figure 2b, we can see that the antibody was immobilized on the PS-MA surface, indicating that the EDC/NHS activation is effective. Figure 2d shows the substrate with activated PS-MA with the addition of PEG (8000), which was added to the solution prior to spin coating. After we put FITC labeled anti-GFAP on it, the fluorescence intensity increased significantly compared with Figure 2c. An explanation for this is as follows. According to the previous report, PEG can help increase the light collection efficiency and enhance the fluorescence intensity.^[41] Inspired by enzyme-linked immunosorbent assay (ELISA) experiments, we used a “sandwich structure” method to further confirm that the native binding functionality of anti-GFAP antibody to the GFAP protein was not compromised; the results are shown in Figure S5 in the Supporting Information. Herein, we modified the normal anti-GFAP on the PS-MA layer with the same steps described in the Experimental Section, and then put 100 $\mu\text{g mL}^{-1}$ GFAP on the device for 0.5 h to let




Figure 2. Fluorescence microscope images: a) bare substrate; b) PS-MA layer without activated by EDC/NHS; c) PS-MA layer after activated by EDC/NHS; d) activated PS-MA with PEG (8000) on exposure to 100 $\mu\text{g mL}^{-1}$ FITC-labeled anti-GFAP.




Figure 3. a) Schematic of proposed sensing mechanism of the extended solution gate device. b) Representative drain current changes of anti-GFAP modified extended solution gate devices on exposure to 100 ng mL⁻¹ GFAP in 0.05X PBS. PS-MA films were mixed with different molecular weight PEGs. Gate voltage (V_G) and drain voltage (V_D) were set to -2 V relative to the source voltage (V_S).

all the anti-GFAP bind with GFAP as thoroughly as possible. After washing 5 times with 0.05X PBS (Figure S6, Supporting Information), we put 100 $\mu\text{g mL}^{-1}$ FITC labeled anti-GFAP on the device for 0.5 h and then again washed 5 times with 0.05X PBS (scheme shown in Figure S5a, Supporting Information). The fluorescence microscope image is shown in Figure S5b of the Supporting Information, on which the green fluorescence is still apparent. As a control experiment, we used a readily available penicillin binding protein 2a (PBP2a) instead of GFAP keeping other steps the same. Based on the result shown in Figure S5c (Supporting Information), it is difficult to find any green fluorescence from FITC, indicating that anti-GFAP and GFAP bind together specifically.

In an additional FITC experiment (Figure S6, Supporting Information), biotin and FITC-marked streptavidin (known to form a very strong complex together) were used to show the quantity of binding that occurs on samples with and without the addition of PEG. Biotin was covalently bound to the surface of our substrate and subsequently exposed to FITC-streptavidin (simulating an antibody–protein complex). The presence of PEG had no effect on the overall fluorescence intensity in the streptavidin-exposed samples, indicating that the PEG is not responsible for increasing binding of protein to antibodies.

2.2. Sensing Capabilities

The sensing capabilities of anti-GFAP modified OTFT devices with the help of different molecular weight PEGs (200, 400, 1000, 4000, 6000, and 8000, respectively) were first determined by measuring drain current changes on exposure to 100 ng mL⁻¹ GFAP solution; the data are shown in Table S1 (Supporting Information). A schematic of the proposed sensing mechanism is shown in Figure 3a. GFAP is negatively charged in pH = 7.4 PBS, and it was tested by zeta potential measurement in our previous work, which involves coating GFAP on a latex particle and measuring the resulting change in zeta potential.^[38] After the protein was bound to anti-GFAP, the negatively charged species induced higher conductance in p-channel transistors. The negatively charged target proteins induce more negative potential in the extended gate and pull charge carriers (holes) close to the channel region of the p-channel semiconductor and thereby enhance

the drain current. The data are shown in Figure 3b. Each data point was repeated five times and reported as an average, with error bars indicating one standard deviation. It is obvious that the three high molecular weight PEGs lead to significant current change (p-value 1%), while the low molecular weight PEGs were quite close to the “no PEG” control samples. As illustrated in Figure 3a, proteins can penetrate the PS-MA layer, having lower ion density because of the PEG, and bind to antibodies in an environment which has an increased sensing response, as if the Debye screening length were longer than it actually is in this analyte solution (calculated as ≈ 0.7 nm in 1X PBS, to 7.3 nm in 0.01X PBS). The sensing properties for different analyte solutions (1X PBS to 0.05X PBS) were also recorded and are shown in Figure S7 (Supporting Information). According to a previous report,^[31] high molecular weight PEGs can reduce the dielectric constant more effectively than lower ones, consistent with the result that high molecular weight PEG mixed devices can achieve larger current change using similar protein concentrations and device configurations. The drain current change of no antibody device was also recorded and shown in Figure S8 (Supporting Information). There is no obvious current change after the device was exposed to 100 ng mL⁻¹ GFAP.

Furthermore, we investigate the drain current changes on exposure to 100 ng mL⁻¹ GFAP solution under different gate voltage (V_G), as we show in Figure 4, where again each data point was repeated at least five times. According to the results,




Figure 4. Drain current changes of anti-GFAP modified extended solution gate devices on exposure to 100 ng mL⁻¹ GFAP solution with different V_G .




Figure 5. Drain current change of anti-GFAP modified devices.

the current changes increased significantly from 4.8% to 10.5% while V_g was decreased from -5 to -2 V. The logical explanation is that the decreasing V_g set the device to a gate voltage that is much closer to the threshold voltage. When the negatively charged species were attached to the extended solution gate, the influence in drain current change was obvious. Because the lowest possible voltage increases compatibility with aqueous biomolecule solutions, we set V_g as -2 V for all the other tests in this paper.

The responses of the sensors to different protein concentration were observed in a range of 0.5 – 100 ng mL $^{-1}$; the data are shown in Table S2 (Supporting Information). The detection limit of this sensor is calculated as 1.0 ng mL $^{-1}$ based on a noise reading of 1.75 (calculation based on our blank samples), and the average current change for that concentration is 2.4% (shown in Figure 5). The continuous testing on one device indicates good stability of the GFAP sensor. In a related control experiment, devices lacking antibody were also measured by directly exposing PS-MA film to 100 ng mL $^{-1}$ GFAP solution, and there is almost no current change (shown in Figure S8 of the Supporting Information).

To further portray the stability of the extended solution gate sensor, drain current changes were recorded every 2 min during a 30 min period after $0.05X$ PBS was dropped on the device. The final drain current change was no more than 6% compared with $I_{\text{drain}0}$ (the first drain current of the device), as shown in Figure 6a. The slight drain current change, occurring over a much longer time than the responses to GFAP, can be attributed to the ions in PBS attaching to the PS-MA film.

We also performed selectivity experiments, as an initial investigation of whether this type of sensor could provide a GFAP response in the presence of other bio-analytes. We chose PBP2a, an appropriately sized protein with a similar negative charge at neutral pH,^[42] and small molecule 17α -hydroxyprogesterone (17α -OHP) of the

physiologically relevant steroid hormone family as interferents,^[43] both of them at 100 ng mL $^{-1}$ in $0.05X$ PBS, the same concentration as used for GFAP. As shown in Figure 6b,c, the drain current changes were slight. Finally, to ensure that the GFAP signal was observable over signals from interfering analytes, we mixed PBP2a, 17α -OHP, and GFAP together in $0.05X$ PBS. The concentration of all these materials is 100 ng mL $^{-1}$, data from which are shown in Figure 6d. After the mixed solution was dropped on the device, a dramatic drain current change was observed. The current change ratio is 9.9% (after correcting for drift in the base line), which is similar to the pure GFAP current change we measured, and also on a faster time scale than current changes seen in drift and control experiments. This provides a preliminary indication that our device can signal the presence of GFAP in a more complex environment.

A plausible explanation for the increase of current change after PEG was mixed in the bioreceptor layer is as follows. The increased drain current change can be attributed to the presence of high molecular weight PEGs. Since high molecular weight PEGs can effectively reduce the dielectric constant and keep a low ion density environment for the binding proteins, the effective-Debye screening length increased, potentially leading to a larger drain current response. We also considered the possibility that the presence of the high molecular weight PEG promoted the penetration of analyte protein deeper into the receptor layer. However, in an additional fluorescence experiment shown in Figure S6 (Supporting Information), we saw that the attached protein concentration did not increase in the presence of PEG on the film. This supports the earlier explanation.




Figure 6. Drain current change of anti-GFAP modified devices a) in $0.05X$ PBS for 30 min; b) after 100 ng mL $^{-1}$ PBP2a; c) after 100 ng mL $^{-1}$ 17α -OHP; d) after the mixed solution (composed of 100 ng mL $^{-1}$ PBP2a, 100 ng mL $^{-1}$ 17α -OHP, and 100 ng mL $^{-1}$ GFAP) dropped on the anti-GFAP modified device.

3. Conclusion

In summary, we described a novel OFET-based biosensor with an extended solution gate structure for label-free GFAP detection with a limit of detection well within the concentration of interest. The extended solution gate structure separates the sensing area from the semiconductor and works without the help of the reference electrode, which combines stability and simplicity. The bioreceptor layers of our devices were mixed with different molecular weight PEGs to help overcome the Debye screening length limitations. As a result, we found that higher molecular weight PEGs can help the sensor achieve better sensitivity. Different V_g were also investigated from -5 to -2 V, showing that the sensitivity is higher under a lower V_g . Finally, the stability and selectivity were observed by recording real-time drain current changes and putting different interferent solutions on the devices. The sensor could sense GFAP in the presence of the interferents. The results establish the use of the extended solution gate and moderately polar bioreceptor layer additives as synergistic strategies for improving protein biosensor performance.

4. Experimental Section

Materials and Devices Fabrication: All the chemical materials were purchased from Sigma-Aldrich without further purification. GFAP from human brain and polyclonal anti-GFAP (ab4674) were purchased from EMD Millipore. Buffer solution was purchased as 10X concentrated PBS for bioreagent, "suitable for cell culture and molecular biology." Highly n-doped (100) silicon wafers (as gate electrodes) with 70 nm SiO_2 (as dielectric layers) were divided into 1×1 in. substrates. After cleaning by piranha solution (DANGER corrosive!), they were sonicated in water, acetone, and isopropanol, and then dried by forced N_2 . Substrates were further cleaned by oxygen plasma (100 W, 3 min) and then annealed in a 100 °C vacuum oven with exposure to hexamethyldisilazane (HMDS) for 2 h. Next, pentacene was thermally evaporated on half of each HMDS-treated substrate surface with a thickness of 50 nm at a rate of 0.4 Å s^{-1} . The chamber pressure during deposition was lower than 4×10^{-6} Torr. Then, gold electrodes (50 nm) were thermally evaporated through an interdigitation mask (shown in Figure S1 in the Supporting Information) and deposited on the pentacene film with a chamber pressure about 5×10^{-6} Torr. The rate was 0.4 Å s^{-1} and the channel width/length was 28 ($W = 7 \text{ mm}$, $L = 0.25 \text{ mm}$).

Antibody Immobilization: On the other half of each substrate, we manually etched $8 \times 8 \text{ mm}$ SiO_2 to expose silicon for the extended solution gate sensing area. The carboxylic acid groups of PS-MA were activated by EDC and NHS. Normally, 10 mg PS-MA and 30 mg EDC were first dissolved in 0.5 mL anhydrous dichloromethane and 0.5 mL anhydrous N,N' -dimethylformamide mixed solvent. After stirring at room temperature for 1 h, 15 mg NHS was then added into the mixture with stirring for another 2 h. The resulting mixture was purified through a 0.45 µm filter and then mixed with 5 mg mL^{-1} of one of a series of different molecular weight PEGs (200, 400, 1000, 4000, 6000, and 8000), with continued stirring at room temperature for half hour. The final mixture was spin-coated on the exposed silicon at a speed of 3000 rpm for 90 s. Then the device surface was carefully washed with DI water to remove excess EDC and NHS and dried in room temperature for antibody modification. Anti-GFAP (1 mg mL^{-1} in 0.05X PBS) was covalently attached to the activated PS-MA surface for 6 h and then gently washed with PBS to remove any noncovalently bound antibodies. To avoid water evaporation and antibody contamination, the samples were maintained in a humid, sealed vessel during the reactions. As control experiments: the devices without anti-GFAP were prepared by

putting one drop of 0.05X PBS on the EDC/NHS activated PS-MA film for 6 h; activated PS-MA without PEG was prepared to make devices with the same steps to compare the influence of PEG.

Apparatus: Electronic analysis of OFETs was conducted on an Agilent 4155C semiconductor parameter analyzer in air. $^1\text{H-NMR}$ spectra were recorded on Bruker Avance (300 MHz/400 MHz) spectrometers. The oxygen plasma treatments were done on a Technics West Inc. (PEII-A) plasma system. Fluorescence images were taken by the fluorescence microscope Olympus IX71.

Supporting Information

Supporting Information is available from the Wiley Online Library or from the author.

Acknowledgements

The authors thank the National Institutes of Health for funding. Research reported in this publication was supported by the National Institute Of Biomedical Imaging And Bioengineering of the National Institutes of Health under Award Number R21EB018426. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. J.D. thanks the National Science Foundation for a Predoctoral Fellowship. The authors appreciate Su-Chang Mun's graphical artworks.

Received: December 9, 2016

Revised: January 24, 2017

Published online:

- [1] Y. Zang, F. Zhang, D. Huang, C. A. Di, D. Zhu, *Adv. Mater.* **2015**, 27, 7979.
- [2] T. Minami, Y. Sasaki, T. Minamiki, S. Wakida, R. Kurita, O. Niwa, S. Tokito, *Biosens. Bioelectron.* **2016**, 81, 87.
- [3] Y. Shintani, S. Ibori, K. Igarashi, T. Naramura, M. Inaba, H. Kawarada, *Electrochim. Acta* **2016**, 212, 10.
- [4] M. Kaisti, Q. Zhang, A. Prabhu, A. Lehmusvuori, A. Rahman, K. Levon, *IEEE Trans. Electron Devices* **2015**, 62, 2628.
- [5] K. Melzer, V. D. Bhatt, E. Jaworska, R. Mittermeier, K. Maksymiuk, A. Michalska, P. Lugli, *Biosens. Bioelectron.* **2016**, 84, 7.
- [6] D. Khim, E. Y. Shin, Y. Xu, W. T. Park, S. H. Jin, Y. Y. Noh, *ACS Appl. Mater. Interfaces* **2016**, 8, 17416.
- [7] T. Minamiki, T. Minami, P. Koutnik, P. Anzenbacher Jr., S. Tokito, *Anal. Chem.* **2016**, 88, 1092.
- [8] M. Magliulo, K. Manoli, E. Macchia, G. Palazzo, L. Torsi, *Adv. Mater.* **2015**, 27, 7528.
- [9] C. Zhang, P. Chen, W. Hu, *Chem. Soc. Rev.* **2015**, 44, 2087.
- [10] J. F. M. Hardigree, H. E. Katz, *Acc. Chem. Res.* **2014**, 47, 1369.
- [11] C. Liao, F. Yan, *Polym. Rev.* **2013**, 53, 352.
- [12] L. Torsi, M. Magliulo, K. Manoli, G. Palazzo, *Chem. Soc. Rev.* **2013**, 42, 8612.
- [13] A. N. Sokolov, B. C. K. Tee, C. J. Bettinger, J. B. H. Tok, Z. Bao, *Acc. Chem. Res.* **2012**, 45, 361.
- [14] A. Operamolla, G. M. Farinola, *Eur. J. Org. Chem.* **2011**, 2011, 423.
- [15] W. Huang, K. Besar, R. LeCover, A. M. Rule, P. N. Breyse, H. E. Katz, *J. Am. Chem. Soc.* **2012**, 134, 14650.
- [16] K. Manoli, M. Magliulo, M. Y. Mulla, M. Singh, L. Sabbatini, G. Palazzo, L. Torsi, *Angew. Chem., Int. Ed.* **2015**, 54, 12562.
- [17] E. Macchia, D. Alberga, K. Manoli, G. F. Mangiatordi, M. Magliulo, G. Palazzo, F. Giordano, G. Lattanzi, L. Torsi, *Sci. Rep.* **2016**, 6, 28085.

- [18] M. Magliulo, D. De Tullio, I. Vikholm-Lundin, W. M. Albers, T. Munter, K. Manoli, G. Palazzo, L. Torsi, *Anal. Bioanal. Chem.* **2016**, 408, 3943.
- [19] M. Magliulo, A. Mallardi, M. Y. Mulla, S. Cotrone, B. R. Pistillo, P. Favia, I. Vikholm-Lundin, G. Palazzo, L. Torsi, *Adv. Mater.* **2013**, 25, 2090.
- [20] M. Singh, M. Y. Mulla, M. V. Santacroce, M. Magliulo, C. Di Franco, K. Manoli, D. Altamura, C. Giannini, N. Cioffi, G. Palazzo, G. Scamarcio, L. Torsi, *J. Phys. D: Appl. Phys.* **2016**, 49, 275101.
- [21] G. Palazzo, D. De Tullio, M. Magliulo, A. Mallardi, F. Intranuovo, M. Y. Mulla, P. Favia, I. Vikholm-Lundin, L. Torsi, *Adv. Mater.* **2015**, 27, 911.
- [22] M. Y. Mulla, E. Tuccori, M. Magliulo, G. Lattanzi, G. Palazzo, K. Persaud, L. Torsi, *Nat. Commun.* **2015**, 6, 6010.
- [23] S. Lai, M. Demelas, G. Casula, P. Cosseddu, M. Barbaro, A. Bonfiglio, *Adv. Mater.* **2013**, 25, 103.
- [24] M. Demelas, S. Lai, G. Casula, E. Scavetta, M. Barbaro, A. Bonfiglio, *Sens. Actuators, B* **2012**, 171–172, 198.
- [25] W. Tang, C. Jiang, Q. Li, W. Hu, L. Feng, Y. Huang, J. Zhao, S. Chen, X. Guo, *IEEE Electron Device Lett.* **2016**, 37, 1002.
- [26] M.-Y. Lin, W.-Y. Hsu, Y.-S. Yang, J.-W. Huang, Y.-L. Chung, H. Chen, *Anal. Bioanal. Chem.* **2016**, 408, 4785.
- [27] N. H. Al-Hardan, M. A. Abdul Hamid, N. M. Ahmed, A. Jalar, R. Shamsudin, N. K. Othman, L. Kar Keng, W. Chiu, H. N. Al-Rawi, *Sensors* **2016**, 16, 839.
- [28] Z. Iskierko, M. Sosnowska, P. S. Sharma, T. Benincori, F. D'Souza, I. Kaminska, K. Fronc, K. Noworyta, *Biosens. Bioelectron.* **2015**, 74, 526.
- [29] S. G. Lemay, C. Laborde, C. Renault, A. Cossetini, L. Selmi, F. P. Widdershoven, *Acc. Chem. Res.* **2016**, 49, 2355.
- [30] N. Gao, W. Zhou, X. Jiang, G. Hong, T. M. Fu, C. M. Lieber, *Nano Lett.* **2015**, 15, 2143.
- [31] K. Arnold, A. Herrmann, L. Pratsch, K. Gawrisch, *Biochim. Biophys. Acta, Biomembr.* **1985**, 815, 515.
- [32] E. M. Hol, M. Pekny, *Curr. Opin. Cell Biol.* **2015**, 32, 121.
- [33] L. F. Eng, *J. Neuroimmunol.* **1985**, 8, 203.
- [34] K. Ishida, K. Kaneko, T. Kubota, Y. Itoh, T. Miyatake, M. Matsushita, M. Yamada, *J. Neurol. Sci.* **1997**, 151, 41.
- [35] C. A. Mayer, R. Brunkhorst, M. Niessner, W. Pfeilschifter, H. Steinmetz, C. Foerch, *PLoS ONE* **2013**, 8, e62101.
- [36] K. Kawata, C. Y. Liu, S. F. Merkel, S. H. Ramirez, R. T. Tierney, D. Langford, *Neurosci. Biobehav. Rev.* **2016**, 68, 460.
- [37] F. K. Korley, R. Diaz-Arrastia, A. Wu, J. K. Yue, G. T. Manley, H. I. Sair, J. V. Eyk, A. D. Everett, *J. Neurotrauma* **2016**, 33, 215.
- [38] W. Huang, K. Besar, R. LeCover, P. Dulloor, J. Sinha, J. F. Martínez Hardigree, C. Pick, J. Swavola, A. D. Everett, J. Frechette, M. Bevan, H. E. Katz, *Chem. Sci.* **2014**, 5, 416.
- [39] C. E. Efstathiou, *Talanta* **2006**, 69, 1068.
- [40] A. Frank Jr., T. P. Dorielle, B. Shekhar, *J. Phys.: Conf. Ser.* **2010**, 224, 012134.
- [41] Z. Gorocs, E. McLeod, A. Ozcan, *Sci. Rep.* **2015**, 5, 10999.
- [42] N. Helassa, W. Vollmer, E. Breukink, T. Vernet, A. Zapun, *FEBS J.* **2012**, 279, 2071.
- [43] A. Rebarber, N. S. Fox, C. K. Klauser, N. B. Istwan, D. J. Rhea, G. J. Stanziano, D. H. Saltzman, *J. Matern.-Fetal Neonat. Med.* **2010**, 23, 1139.